Sandoz
Sandoz, a division of Novartis, is a global leader in the pharmaceutical industry, headquartered in Switzerland (CH). Founded in 1886, Sandoz has established itself as a pioneer in generic and biosimilar medicines, focusing on high-quality, affordable healthcare solutions. With a strong presence in Europe, North America, and emerging markets, the company is dedicated to improving patient access to essential medications. Sandoz's core offerings include a diverse range of generic pharmaceuticals, biosimilars, and over-the-counter products, distinguished by their rigorous quality standards and innovative approaches. The company has achieved significant milestones, including the launch of several groundbreaking biosimilars, solidifying its position as a trusted partner in the healthcare sector. With a commitment to sustainability and patient-centric solutions, Sandoz continues to shape the future of medicine.
DitchCarbon Score
How does Sandoz's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Sandoz's score of 20 is higher than 87% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Sandoz's reported carbon emissions
In 2023, Sandoz reported total carbon emissions of approximately 2,278,340,000 kg CO2e, comprising 82,850,000 kg CO2e from Scope 1 and 143,830,000 kg CO2e from Scope 2 emissions. Notably, Scope 3 emissions accounted for about 2,051,660,000 kg CO2e, highlighting the significant impact of upstream activities, particularly from purchased goods and services, which contributed approximately 1,480,000,000 kg CO2e. Comparatively, in 2022, Sandoz's emissions were approximately 2,234,400,000 kg CO2e, with Scope 1 emissions at 79,940,000 kg CO2e and Scope 2 emissions at 151,480,000 kg CO2e. The 2021 data showed total emissions of about 233,000,000 kg CO2e, with Scope 1 at 75,620,000 kg CO2e and Scope 2 at 158,430,000 kg CO2e. Sandoz has committed to near-term emissions reduction targets, although specific numerical targets have not been disclosed. The company is not currently committed to a net-zero target. Their emissions intensity metrics indicate a consistent GHG emissions intensity of approximately 0.00002343 tCO2e per million USD in sales and 10,020 kg CO2e per full-time employee across the reported years. Sandoz's headquarters is located in Switzerland (CH), and they operate within the Pharmaceuticals, Biotechnology, and Life Sciences sector, reflecting their commitment to addressing climate change through improved sustainability practices.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2021 | 2022 | 2023 | |
|---|---|---|---|
| Scope 1 | 75,620,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 158,430,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Sandoz is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
